AestheticsFeatured Articles

Increased Trend of Cosmetic Procedures in Patients With Psoriasis Who Attain 75% or Greater Improvement

By August 25, 2020No Comments

Featured Article

Featured Article

A survey was conducted at a single dermatology center to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.

Read more

A survey was conducted at a single dermatology center to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.

Michelle E. Walters MD, Delphine J. Lee MD PhD, Paul S. Yamauchi MD PhD

Psoriasis is a chronic skin condition with a negative impact on patient quality of life. The National Psoriasis Foundation states that an acceptable response to psoriasis treatment is at least a 75% reduction in body surface area (BSA) at 3 months after initiation of treatment.

This reduction in BSA has been associated with improvement in quality of life, with clearance rates of clear to almost clear leading to an even greater improvement in quality of life.2,3 To date, there have been no studies examining the relationship between improvement in quality of life following a reduction in BSA, and the increased utilization of cosmetic procedures. Here, we examine the relationship between quality of life and the use of various cosmetic procedures in patients treated for psoriasis with systemic and biologic therapies who achieved at least 75% reduction in BSA.

This was a retrospective study assessing quality of life and the use of cosmetic procedures in psoriasis patients after attaining a75% or greater reduction of the body surface area with biologic agents only, systemic agents only, or a combination of both. This study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki. All patients provided informed consent.

Read Full Article Now
Article Cited in this Post

You May Also Like

Journal of Drugs in Dermatology JDD Article About Assessing Patient Preferences for Atopic Dermatitis Treatment: A Review Article of Discrete Choice Experiments

Assessing Patient Preferences for Atopic Dermatitis Treatment: A Review Article of Discrete Choice Experiments

| Featured Articles, The Latest | No Comments
JDD Article Highlights Struggling with treatment adherence in your atopic dermatitis (AD) patients? AD is a widespread inflammatory skin condition, but even with various treatment options, poor adherence - especially to…
Journal of Drugs in Dermatology JDD article about Dermatologic Procedures for the Treatment of Seborrheic Dermatitis

Dermatologic Procedures for the Treatment of Seborrheic Dermatitis

| Featured Articles, The Latest | No Comments
Did You Miss It? Published early online in August, the JDD article titled “Dermatologic Procedures for the Treatment of Seborrheic Dermatitis” reviews alternative dermatologic procedures for treating Seborrheic Dermatitis (SD), offering clinicians…
Journal of Drugs in Dermatology JDD article titled The ABCs of JAKis: A Clinician's Guide to Safety and Monitoring of the Systemic JAK Inhibitors

The ABCs of JAKis: A Clinician’s Guide to Safety and Monitoring of the Systemic JAK Inhibitors

| Featured Articles, The Latest | No Comments
JDD Article Highlight Curious about the latest in dermatology treatments? Janus Kinase Inhibitors (JAKis) are gaining traction as a powerful tool for various skin conditions—but there’s more to the story.…

Leave a Reply